羅貝考昔
Robenacoxib
5-ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]phenyl acetic acid
別名: Onsior · robenacoxibum · robénacoxib
由 VetSheet 獸醫團隊審訂更新於 2026年4月5日本內容以實證獸醫文獻為本
劑量為持牌獸醫專業人員的臨床參考。請務必對照最新藥品說明書及個別病患確認。
各物種劑量
🌎 NA — North America🌍 EU — Europe
狗
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Pain and inflammation associated with chronic osteoarthritis | 1 mg/kg with a range of 1-2 mg/kg | PO | once daily | Discontinue after 10 days if no clinical improvement seen | 🌎 NA |
| Pain and inflammation associated with orthopedic or soft tissue surgery | 2 mg/kg | SC | once | — | 🌎 NA |
| Perioperative analgesia (orthopaedic and soft tissue surgery) | 2 mg/kg | SC | q24h | Maximum of 2 doses | 🌍 EU |
| Acute and chronic musculoskeletal disorders | 1-2 mg/kg | PO | q24h | Discontinue after 10 days if no clinical improvement | 🌍 EU |
- Pain and inflammation associated with chronic osteoarthritis: Give at the same time every day. For long term treatment, can adjust to lowest effective dose.
- Pain and inflammation associated with orthopedic or soft tissue surgery: Administer approximately 30 minutes before the start of surgery.
- Perioperative analgesia (orthopaedic and soft tissue surgery): Administer approximately 30 minutes before the start of surgery.
- Acute and chronic musculoskeletal disorders: Do not administer with food. Monitoring is recommended for long-term treatment (>12 weeks).
貓
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Acute pain and inflammation associated with musculoskeletal disorders | 1 mg/kg; with a range of 1-2.4 mg/kg | PO | once daily | up to 6 days | 🌎 NA |
| Pain and inflammation associated with chronic osteoarthritis (Note: Label likely intended for surgical pain based on injection formulation) | 2 mg/kg | SC | once | — | 🌎 NA |
| Perioperative analgesia | 2 mg/kg | SC | q24h | Maximum of 2 doses | 🌍 EU |
| Acute and chronic musculoskeletal pain and inflammation | 1-2 mg/kg | PO | q24h | As directed by veterinarian | 🌍 EU |
- Acute pain and inflammation associated with musculoskeletal disorders: Equates to 1 tablet for cats weighing 2.5-<6 kg and 2 tablets for cats weighing 6 kg-<12 kg. Give either without food or with a small amount of food; tablets should not be divided or broken.
- Pain and inflammation associated with chronic osteoarthritis (Note: Label likely intended for surgical pain based on injection formulation): Administer approximately 30 minutes before the start of surgery.
- Perioperative analgesia: Administer approximately 30 minutes before the start of surgery.
- Acute and chronic musculoskeletal pain and inflammation: May be mixed with a small amount of food. Monitoring is recommended for long-term treatment (>12 weeks).
劑量為持牌獸醫專業人員的臨床參考。請務必對照最新藥品說明書及個別病患確認。
概覽
羅貝考昔 (Robenacoxib) 是一種專為犬貓設計的高選擇性昔布類 (Coxib) 非類固醇抗發炎藥 (NSAID)。
主要臨床特點包括：
- 組織選擇性：它具有獨特的藥代動力學特徵，能迅速從中央血液區間清除，但在活動性發炎部位（如發炎的關節）能維持較高濃度且作用時間更長。這種「組織保留」效應有助於在最大化療效的同時，將全身性副作用降至最低。
- 高 COX-2 專一性：在犬隻體內對 COX-2 的選擇性約為 COX-1 的 140 倍，在貓體內則高達 500 倍，是獸醫學中對 COX-2 最具專一性的 NSAID 之一。
- 適應症：主要用於控制犬隻的慢性骨關節炎疼痛、貓的急性肌肉骨骼疼痛，以及兩種動物的軟組織或骨科手術之圍手術期疼痛。
作用機制
Robenacoxib exerts its anti-inflammatory and analgesic effects by selectively inhibiting the Cyclooxygenase-2 (COX-2) enzyme.
Arachidonic Acid → COX-2 Enzyme → Prostaglandin E2 (PGE2) and other inflammatory mediators.
By specifically targeting the inducible COX-2 isoform, robenacoxib effectively blunts the production of prostaglandins responsible for pain, inflammation, and fever. Because it largely spares the constitutive COX-1 enzyme, it preserves the homeostatic prostaglandins that are crucial for maintaining gastrointestinal mucosal integrity, renal blood flow, and normal platelet function.
安全性與警告
禁忌症
- Patients with active gastrointestinal ulcers
- Hypersensitivity to robenacoxib or its excipients
- Dogs with hepatic disease
- Dehydrated, hypovolaemic, or hypotensive patients
- Patients with pre-existing gastrointestinal disease or ulceration
- Patients with blood clotting disorders
- Pregnant or lactating animals
- Dogs < 12 weeks of age or < 2.5 kg body weight
- Cats < 16 weeks of age or < 2.5 kg body weight
- Perioperative use in animals with renal disease (not advisable)
不良反應
- Decreased appetite
- Blood in feces (melena/hematochezia)
- Mild gastrointestinal signs (vomiting, soft feces, diarrhea)
- Gastrointestinal ulceration or bleeding (rare but severe)
- Renal toxicity (especially if hypotensive or dehydrated)
- Hepatic accumulation (in patients with pre-existing liver disease)
注意事項
Strict Veterinary Monitoring Required: Use with extreme caution in patients with impaired cardiac or renal function, dehydration, hypovolemia, hypotension, or in cats with hepatic dysfunction.
- Washout Period: Do not use concurrently with corticosteroids or other NSAIDs. A treatment-free period of at least 24 hours (accounting for the half-life of the previous drug) should be observed before starting robenacoxib.
- Renal Perfusion: Use cautiously with drugs that affect renal blood flow (e.g., diuretics, ACE inhibitors) due to the risk of renal toxicity.
- Reproduction: Safety has not been established in pregnant or lactating animals; use is not recommended.
藥物相互作用
Some NSAIDs can reduce effects on blood pressure
May increase the risk of gastrointestinal toxicity (e.g., ulceration, bleeding, vomiting, diarrhea)
May increase the risk of gastrointestinal toxicity (e.g., ulceration, bleeding, vomiting, diarrhea)
NSAIDs may increase serum levels
Administration has increased plasma levels of celecoxib in humans and potentially could also affect robenacoxib levels in dogs
NSAIDs may reduce the saluretic and diuretic effects
As robenacoxib is highly bound to plasma proteins (>99%), it may displace other highly bound drugs or be displaced by them, potentially leading to increased serum levels and toxicity
Serious toxicity has occurred when NSAIDs have been used concomitantly; use together with extreme caution
May enhance the risk of nephrotoxicity development
Increased risk of severe gastrointestinal ulceration and renal toxicity. Require a 3-5 day wash-out period.
Increased risk of severe gastrointestinal ulceration and bleeding.
Increased risk of nephrotoxicity.
監測
- Baseline and periodic physical examinations to assess clinical efficacy and adverse effects
- Baseline and periodic CBC, serum biochemistry (liver and renal function), electrolytes, and urinalysis
- For long-term therapy in dogs: Monitor liver enzymes at the start of therapy, and after 2, 4, and 8 weeks; then every 3-6 months
- Discontinue therapy if liver enzymes increase markedly or if accompanied by clinical signs (anorexia, apathy, vomiting)
- Clinical response (reduction in pain and inflammation)
- Gastrointestinal signs (monitor for vomiting, diarrhea, or melena)
- Renal parameters (BUN, Creatinine, USG) and hepatic enzymes, especially prior to anesthesia or during long-term therapy (>12 weeks)
藥物動力學
半衰期
吸收
Peak blood concentrations occur approximately 30 minutes after dosing in both dogs and cats. In dogs, food decreases peak levels somewhat. In cats, a small amount of food does not impact absorption.
分佈
Highly bound to plasma proteins (>99%). Robenacoxib persists longer and at higher concentrations at sites of inflammation (e.g., inflamed joints) than in the central blood compartment.
代謝
Extensively metabolized by the liver in both dogs and cats. It does not appear to induce hepatic enzymes in dogs.
排除
In dogs, excretion is primarily biliary (~65%) with the remainder excreted renally. In cats, elimination is 70% biliary and 30% renal.
過量
Acute overdoses may potentially cause gastrointestinal, kidney, or liver toxicity.
Interestingly, chronic toxicity studies in healthy young dogs (up to 10 mg/kg/day for 6 months) and cats (up to 10 mg/kg SC for 3 days) did not produce signs of toxicity.
Treatment: If an acute overdose occurs, symptomatic and supportive therapy is recommended. This may include the administration of gastrointestinal protective agents (e.g., sucralfate, omeprazole), IV fluid therapy for forced diuresis and renal support, and contacting an animal poison control center for guided management.
可用產品
劑型
- Flavored oral tablets (canine and feline)
- Solution for injection
- 5 mg flavoured tablets (dogs)
- 10 mg flavoured tablets (dogs)
- 20 mg flavoured tablets (dogs)
- 40 mg flavoured tablets (dogs)
- 6 mg flavoured tablets (cats)
- 20 mg/ml injectable solution
獸醫用
- Robenacoxib Flavored Oral Tablets (dogs): 5 mg, 10 mg, 20 mg, 40 mg
- Robenacoxib Flavored Tablets (cats): 6 mg
- Robenacoxib Solution for Injection: 20 mg/mL in 20 mL multi-dose vials
- Onsior 5 mg flavoured tablets for dogs
- Onsior 10 mg flavoured tablets for dogs
- Onsior 20 mg flavoured tablets for dogs
- Onsior 40 mg flavoured tablets for dogs
- Onsior 6 mg flavoured tablets for cats
- Onsior 20 mg/ml solution for injection
各地核准狀態
POM-V classification
POM-V classification
暫無法規資料: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
儲存與穩定性
Store canine flavored tablets at 25°C (77°F) or less. Store feline flavored tablets at no more than 30°C (86°F). The injection should be stored in the refrigerator (2°-8°C) in its original outer carton.
飼主須知
Onsior® (羅貝考昔) 是一種用於緩解寵物疼痛和發炎的藥物。為了確保安全有效地使用，請遵循以下指引：
- 對於犬隻：請空腹給藥。在飯前或飯後至少 30 分鐘給予藥物。
- 對於貓咪：可以空腹或與少量食物一起給予。請勿將藥錠剝半、切碎或壓碎。
- 處理注意事項：接觸藥物後請洗手。即將分娩的孕婦在處理此藥物時應戴上手套。
- 需注意的症狀：如果您的寵物出現以下任何不適症狀，請立即停藥並聯繫您的獸醫師：
- 嚴重或帶血的嘔吐或腹瀉
- 食慾不振或極度嗜睡（無精打采）
- 眼白或牙齦發黃（黃疸）
- 虛脫或無力
- 絕對不要在未諮詢獸醫師的情況下，讓您的寵物在服用此藥期間同時服用任何其他止痛藥（如阿斯匹靈、布洛芬或其他獸醫用 NSAID）或類固醇。
VetSheet 藥物參考供持牌獸醫專業人員作臨床決策輔助之用，不能取代專業判斷或廠方最新藥品說明書。